Literature DB >> 11417933

Is electroconvulsive therapy effective for the depressed patient with comorbid borderline personality disorder?

C DeBattista1, K Mueller.   

Abstract

Among the more common current indications for electroconvulsive therapy (ECT) is treatment-resistant depression. Treatment resistance is correlated with a number of factors, including the presence of comorbid personality disorders, such as borderline personality disorder (BPD). A detailed review of the literature was undertaken and very few reports or studies have dealt specifically with ECT in borderline patients. Thirteen original reports on ECT outcome in personality disordered patients were identified. Depressed patients with a personality disorder, particularly BPD, may have a poorer outcome on some measures. However, the available data suggests that depression in these patients can be effectively treated with ECT. The depressed, borderline patient appears to have two distinct disorders, one which is responsive to ECT and the other which is not. Unfortunately, the literature is limited by lack of rigorous randomized treatment studies, lack of long-term follow-up, and other methodological weaknesses. Clinical guidelines are suggested.

Entities:  

Mesh:

Year:  2001        PMID: 11417933     DOI: 10.1097/00124509-200106000-00002

Source DB:  PubMed          Journal:  J ECT        ISSN: 1095-0680            Impact factor:   3.635


  3 in total

Review 1.  Psychopharmacology of borderline personality disorder.

Authors:  Y Pritham Raj
Journal:  Curr Psychiatry Rep       Date:  2004-06       Impact factor: 5.285

Review 2.  Electroconvulsive therapy: Part II: a biopsychosocial perspective.

Authors:  Nancy A Payne; Joan Prudic
Journal:  J Psychiatr Pract       Date:  2009-09       Impact factor: 1.325

3.  Pharmacological strategies in the prevention of relapse after electroconvulsive therapy.

Authors:  Joan Prudic; Roger F Haskett; W Vaughn McCall; Keith Isenberg; Thomas Cooper; Peter B Rosenquist; Benoit H Mulsant; Harold A Sackeim
Journal:  J ECT       Date:  2013-03       Impact factor: 3.635

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.